The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
Open accessAbstract
Anandamide was the first brain metabolite shown to act as a ligand of “central” CB1 cannabinoid receptors. Here we report that the endogenous cannabinoid potently and selectively inhibits the proliferation of human breast cancer cells in vitro . Anandamide dose-dependently inhibited the proliferation of MCF-7 and EFM-19 cells with IC 50 values between 0.5 and 1.5 μM and 83–92% maximal inhibition at 5–10 μM. The proliferation of several other nonmammary tumoral cell lines was not affected by 10 μM anandamide. The anti-proliferative effect of anandamide was not due to toxicity or to apoptosis of cells but was accompanied by a reduction of cells in the S phase of the cell cycle. A stable analogue of anandamide ( R )-methanandamide, another endogenous cannabinoid, 2-arachidonoylglycerol, and the synthetic cannabinoid HU-210 also inhibited EFM-19 cell proliferation, whereas arachidonic acid was much less effective. These cannabimimetic substances displaced the binding of the selective cannabinoid agonist [ 3 H]CP 55,940 to EFM-19 membranes with an order of potency identical to that observed for the inhibition of EFM-19 cell proliferation. Moreover, anandamide cytostatic effect was inhibited by the selective CB1 receptor antagonist SR 141716A. Cell proliferation was arrested by a prolactin mAb and enhanced by exogenous human prolactin, whose mitogenic action was reverted by very low (0.1–0.5 μM) doses of anandamide. Anandamide suppressed the levels of the long form of the prolactin receptor in both EFM-19 and MCF-7 cells, as well as a typical prolactin-induced response, i.e., the expression of the breast cancer cell susceptibility gene brca1 . These data suggest that anandamide blocks human breast cancer cell proliferation through CB1-like receptor-mediated inhibition of endogenous prolactin action at the level of prolactin receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationPharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl
Somasundaram, K., Zhang, H., Zeng, Y.-X., Houvras, Y., Peng, Y., Zhang, H., Wu, G. S., Licht, J. D., Weber, B. L., & El-Deiry, W. S. (1997) · Nature · doi:10.1038/38291 · Cited by 509
Felder, C. C., Briley, E. M., Axelrod, J., Simpson, J. T., Mackie, K., & Devane, W. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7656 · Cited by 475
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…tyrosine kinase activity (Casanova et al., 2003; Mimeault et al., 2003), and a decrease in the activity and/or expression of nerve growth factor or vascular endothelial growth factor tyrosine kinase receptors and prolactin (De Petrocellis et al., 1998; Melck et al., 2000; Portella et al., 2003).”
BackgroundPharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Self-citationCannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Galve-Roperh, I., Sánchez, C., Cortés, M. L., del Pulgar, T. G., Izquierdo, M., & Guzmán, M. (2000) · Nature Medicine · doi:10.1038/73171 · Cited by 682
Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., & Di Marzo, V. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105247 · Cited by 568
Self-citationCannabinoid receptors and their ligands
Pertwee, R. G., & Ross, R. A. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0341 · Cited by 561
Mitochondria as a Pharmacological Target
Szewczyk, A., & Wojtczak, L. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.1.101 · Cited by 538
The cannabinoid system and immune modulation
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., & Friedman, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524
Antifibrogenic role of the cannabinoid receptor CB2 in the liver
Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J. T., Li, L., Karsak, M., Zimmer, A., Mallat, A., & Lotersztajn, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.050 · Cited by 470
Mechoulam, R., Fride, E., & Di Marzo, V. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00649-9 · Cited by 428
Self-citationDietrich, A., & McDaniel, W. F. (2004) · British Journal of Sports Medicine · doi:10.1136/bjsm.2004.011718 · Cited by 410
BISOGNO, T., MELCK, D., BOBROV, M. Y., GRETSKAYA, N. M., BEZUGLOV, V. V., De PETROCELLIS, L., & Di MARZO, V. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510817 · Cited by 381
Self-citationCarracedo, A., Gironella, M., Lorente, M., Garcia, S., Guzmán, M., Velasco, G., & Iovanna, J. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0169 · Cited by 354
SUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
Sugiura, T., Kobayashi, Y., Oka, S., & Waku, K. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0356 · Cited by 348
De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
Self-citationAnandamide Induces Apoptosis in Human Cells via Vanilloid Receptors
Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., & Finazzi-Agrò, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005722200 · Cited by 347
Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies
Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3846 · Cited by 298
Effects of Marijuana Smoking on the Lung
Tashkin, D. P. (2013) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201212-127fr · Cited by 297
Di Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A., & Kunos, G. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00631.x · Cited by 296
Self-citationTargeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
McKallip, R. J., Lombard, C., Fisher, M., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, P. S., & Nagarkatti, M. (2002) · Blood · doi:10.1182/blood-2002-01-0098 · Cited by 288
Possible endocannabinoid control of colorectal cancer growth
Ligresti, A., Bisogno, T., Matias, I., De Petrocellis, L., Cascio, M. G., Cosenza, V., D’argenio, G., Scaglione, G., Bifulco, M., Sorrentini, I., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00881-3 · Cited by 287
Self-citationBoger, D. L., Sato, H., Lerner, A. E., Hedrick, M. P., Fecik, R. A., Miyauchi, H., Wilkie, G. D., Austin, B. J., Patricelli, M. P., & Cravatt, B. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5044 · Cited by 272
Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M., & Di Marzo, V. (2000) · Endocrinology · doi:10.1210/endo.141.1.7239 · Cited by 265
Self-citationThe CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt
del Pulgar, T. G., Velasco, G., & Guzmán, M. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3470369 · Cited by 259
The fatty acid amide hydrolase (FAAH)
Ueda, N., Puffenbarger, R. A., Yamamoto, S., & Deutsch, D. G. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00190-0 · Cited by 256
Melck, D., Bisogno, T., De Petrocellis, L., Chuang, H.-H., Julius, D., Bifulco, M., & Di Marzo, V. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1105 · Cited by 188
Self-citationMelck, D., Rueda, D., Galve-Roperh, I., De Petrocellis, L., Guzmán, M., & Di Marzo, V. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01639-7 · Cited by 168
Self-citationMcKallip, R. J., Lombard, C., Martin, B. R., Nagarkatti, M., & Nagarkatti, P. S. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033506 · Cited by 143
Dando, I., Donadelli, M., Costanzo, C., Dalla Pozza, E., D'Alessandro, A., Zolla, L., & Palmieri, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.151 · Cited by 128
Antitumorigenic effects of cannabinoids beyond apoptosis.
Freimuth, N., Ramer, R., & Hinz, B. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157735 · Cited by 71
Cannabis Treatments in Obstetrics and Gynecology: A Historical Review
Russo, E. (2002) · Journal of Cannabis Therapeutics · doi:10.1300/j175v02n03_02 · Cited by 71
New trends for the medical treatment of endometriosis
Rocha, A. L. L., Reis, F. M., & Petraglia, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.683783 · Cited by 60
Cannabinoid receptor systems: therapeutic targets for tumour intervention.
Jones, S., & Howl, J. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.749 · Cited by 13
“This CB1-mediated antiproliferative effect was observed in studies with human breast cancer cell (HBCC) lines MCF-7, EFM-19 [68], and T47D [69], and has been attributed to the disruption of both autocrine and paracrine growth mechanisms.”
BackgroundInfluential
Metadata
- Authors
- De Petrocellis, L., Melck, D., Palmisano, A., Bisogno, T., Laezza, C., Bifulco, M., & Di Marzo, V.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-07-07
- Volume
- 95
- Issue
- 14
- Pages
- 8375-8380
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2144898517
- Cited by
- 413
- References
- 38
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.